Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
annexation, assumption, Chaikin, Crimea, disclaimer, Donetsk, EPS, hereinafter, ID, improper, incorrect, Interbank, invasion, led, levied, Luhansk, magnify, predecessor, remediate, remediated, Republic, Russian, separatist, smaller, Society, Somekh, stale, SWIFT, Telecommunication, Ukraine
Filing tables
Filing exhibits
- 20-F Annual report (foreign)
- 12.1 Certification
- 12.2 Certification
- 13.1 Certification
- 15.1 Consent of Kesselman & Kesselman, a Member Firm of Pricewaterhousecoopers International LTD.
- 15.2 Letter from Kesselman & Kesselman, a Member Firm of Pricewaterhousecoopers International LTD.
- 15.3 Consent of Somekh Chaikin, a Member Firm of KPMG International
- Download Excel data file
- View Excel data file
XTLB similar filings
Filing view
External links
Exhibit 13.1
CERTIFICATION PURSUANT TO
18 USC. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of XTL Biopharmaceuticals Ltd. (the “Company”) on Form 20-F for the year ending December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Shlomo Shalev, Chief Executive Officer of the Company, and Itay Weinstein, Chief Financial Officer of the Company, certify, pursuant to 18 USC. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
(1) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
(2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
Date: March 30, 2022 | /s/ Shlomo Shalev |
Shlomo Shalev | |
Chief Executive Officer | |
/s/ Itay Weinstein | |
Itay Weinstein | |
Chief Financial Officer |